{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:48:24Z","timestamp":1790952504160,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFC1704500"],"award-info":[{"award-number":["2018YFC1704500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFC1704505"],"award-info":[{"award-number":["2018YFC1704505"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.apsb.2021.09.013","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:15:04Z","timestamp":1632183304000},"page":"135-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Atractylenolide-I covalently binds to CYP11B2, selectively inhibits aldosterone synthesis, and improves hyperaldosteronism"],"prefix":"10.1016","volume":"12","author":[{"given":"Wenjuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0911-1714","authenticated-orcid":false,"given":"Xiaoying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9161-2173","authenticated-orcid":false,"given":"Gang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2021.09.013_bib1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/j.2040-4603.2014.tb00565.x","article-title":"Regulation of aldosterone synthesis and secretion","volume":"4","author":"Bollag","year":"2014","journal-title":"Compr Physiol"},{"key":"10.1016\/j.apsb.2021.09.013_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1042\/CS20180194","article-title":"Electrolyte transport in the renal collecting duct and its regulation by the renin\u2012angiotensin\u2012aldosterone system","volume":"133","author":"Yamazaki","year":"2019","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.apsb.2021.09.013_bib3","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.amjmed.2006.05.007","article-title":"Water and sodium retention in edematous disorders: role of vasopressin and aldosterone","volume":"119","author":"Schrier","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.apsb.2021.09.013_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tem.2016.01.003","article-title":"Local control of aldosterone production and primary aldosteronism","volume":"27","author":"Lalli","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.apsb.2021.09.013_bib5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.bbadis.2017.12.034","article-title":"Regulation of aldosterone production by ion channels: from basal secretion to primary aldosteronism","volume":"1864","author":"Yang","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.apsb.2021.09.013_bib6","first-page":"1029","article-title":"The biology of normal zona glomerulosa and aldosterone-producing adenoma: pathological implications","volume":"39","author":"Seccia","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.apsb.2021.09.013_bib7","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1001\/jama.1980.03310120039020","article-title":"Hyperaldosteronism, hyperparathyroidism, medullary sponge kidneys, and hypertension","volume":"244","author":"Hellman","year":"1980","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2021.09.013_bib8","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","article-title":"Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension","volume":"150","author":"Sowers","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.apsb.2021.09.013_bib9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.apsb.2021.09.013_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.recesp.2012.07.025","article-title":"Hypertension caused by primary hyperaldosteronism: increased heart damage and cardiovascular risk","volume":"66","author":"Abad-Cardiel","year":"2013","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.apsb.2021.09.013_bib11","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2215\/CJN.01410210","article-title":"Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome","volume":"5","author":"Schrier","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.apsb.2021.09.013_bib12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.pcad.2009.12.004","article-title":"Aldosterone: role in the cardiometabolic syndrome and resistant hypertension","volume":"52","author":"Whaley-Connell","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.apsb.2021.09.013_bib13","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","article-title":"Hypertension: renin\u2012angiotensin\u2012aldosterone system alterations","volume":"116","author":"Te Riet","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.apsb.2021.09.013_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1161\/HYPERTENSIONAHA.119.13772","article-title":"Renin\u2012angiotensin\u2012aldosterone system triple\u2012a analysis for the screening of primary aldosteronism","volume":"75","author":"Burrello","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.apsb.2021.09.013_bib15","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/ijms18051032","article-title":"Aldosterone and mineralocorticoid receptors\u2012physiology and pathophysiology","volume":"18","author":"Funder","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2021.09.013_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/147323000102900103","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy","volume":"29","author":"Sato","year":"2001","journal-title":"J Int Med Res"},{"key":"10.1016\/j.apsb.2021.09.013_bib17","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin\u2012angiotensin\u2012aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.apsb.2021.09.013_bib18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2021.09.013_bib19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.apsb.2021.09.013_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0303-7207(99)00051-9","article-title":"Adrenal zonation: clues from 11\u03b2-hydroxylase and aldosterone synthase","volume":"151","author":"Rainey","year":"1999","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.apsb.2021.09.013_bib21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jsbmb.2014.10.011","article-title":"The CYP11B subfamily","volume":"151","author":"Schiffer","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.apsb.2021.09.013_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1210\/jcem-73-1-99","article-title":"Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor","volume":"73","author":"Santen","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.apsb.2021.09.013_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ab.2009.07.025","article-title":"Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors","volume":"394","author":"LaSala","year":"2009","journal-title":"Anal Biochem"},{"key":"10.1016\/j.apsb.2021.09.013_bib24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.apsb.2021.09.013_bib25","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with cushing's disease: results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.apsb.2021.09.013_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jep.2018.08.023","article-title":"The traditional uses, phytochemistry, and pharmacology of Atractylodes macrocephala Koidz.: a review","volume":"226","author":"Zhu","year":"2018","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.apsb.2021.09.013_bib27","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.3390\/molecules23123234","article-title":"UPLC\u2012MS\/MS of atractylenolide I, atractylenolide II, atractylenolide III, and atractyloside A in rat plasma after oral administration of raw and wheat bran-processed atractylodis rhizoma","volume":"23","author":"Xu","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2021.09.013_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3390\/cancers12020311","article-title":"Cinnamaldehyde enhances antimelanoma activity through covalently binding ENO1 and exhibits a promoting effect with dacarbazine","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2021.09.013_bib29","doi-asserted-by":"crossref","first-page":"E5896","DOI":"10.1073\/pnas.1801745115","article-title":"Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis","volume":"115","author":"Dai","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.09.013_bib30","doi-asserted-by":"crossref","first-page":"40418","DOI":"10.1039\/C7RA06302D","article-title":"Phillygenin attenuates inflammatory responses and influences glucose metabolic parameters by inhibiting Akt activity","volume":"7","author":"Liu","year":"2017","journal-title":"Rsc Adv"},{"key":"10.1016\/j.apsb.2021.09.013_bib31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsbmb.2012.03.002","article-title":"Human aldosterone synthase: recombinant expression in E. coli and purification enables a detailed biochemical analysis of the protein on the molecular level","volume":"132","author":"Hobler","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.apsb.2021.09.013_bib32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/bs.apcsb.2016.07.003","article-title":"Cytochromes P450: history, classes, catalytic mechanism, and industrial application","volume":"105","author":"Cook","year":"2016","journal-title":"Adv Protein Chem Struct Biol"},{"key":"10.1016\/j.apsb.2021.09.013_bib33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.apsb.2018.11.002","article-title":"Glycyrrhetinic acid binds to the conserved P-loop region and interferes with the interaction of RAS-effector proteins","volume":"9","author":"Zhang","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2021.09.013_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jsbmb.2018.11.009","article-title":"SPR-based study of affinity of cytochrome P450s\/redox partners interactions modulated by steroidal substrates","volume":"187","author":"Ershov","year":"2019","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.apsb.2021.09.013_bib35","doi-asserted-by":"crossref","first-page":"105793","DOI":"10.1016\/j.jsbmb.2020.105793","article-title":"Substrate-induced modulation of protein\u2012protein interactions within human mitochondrial cytochrome P450-dependent system","volume":"208","author":"Yablokov","year":"2021","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.apsb.2021.09.013_bib36","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1056\/NEJM199407283310408","article-title":"Disorders of aldosterone biosynthesis and action","volume":"331","author":"White","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2021.09.013_bib37","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s11120-008-9322-1","article-title":"Oxygen activation by cytochrome P450 monooxygenase","volume":"98","author":"Hamdane","year":"2008","journal-title":"Photosynth Res"},{"key":"10.1016\/j.apsb.2021.09.013_bib38","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.copbio.2011.02.008","article-title":"Cytochrome P450: taming a wild type enzyme","volume":"22","author":"Jung","year":"2011","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.apsb.2021.09.013_bib39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/07435809609043731","article-title":"Changed ratios of glucocorticoids\/mineralocorticoids caused by point mutations in the putative I-helix regions of CYP11B1 and CYP11B2","volume":"22","author":"Bottner","year":"1996","journal-title":"Endocr Res"},{"key":"10.1016\/j.apsb.2021.09.013_bib40","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1046\/j.1432-1327.1998.2520458.x","article-title":"Conferring aldosterone synthesis to human CYP11B1 by replacing key amino acid residues with CYP11B2-specific ones","volume":"252","author":"Bottner","year":"1998","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.apsb.2021.09.013_bib41","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10822-007-9128-9","article-title":"Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics","volume":"21","author":"Roumen","year":"2007","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.apsb.2021.09.013_bib42","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1038\/s41467-019-13033-4","article-title":"Elevated aldosterone and blood pressure in a mouse model of familial hyperaldosteronism with ClC-2 mutation","volume":"10","author":"Schewe","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2021.09.013_bib43","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1517\/14728222.2016.1151873","article-title":"The potential of targeting CYP11B","volume":"20","author":"Bernhardt","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.apsb.2021.09.013_bib44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","article-title":"Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)","volume":"69","author":"Bogman","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.apsb.2021.09.013_bib45","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1074\/jbc.RA118.006214","article-title":"Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design","volume":"294","author":"Brixius-Anderko","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2021.09.013_bib46","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bit.22775","article-title":"Recombinant human cytochrome P450 monooxygenases for drug metabolite synthesis","volume":"106","author":"Schroer","year":"2010","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.apsb.2021.09.013_bib47","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1210\/me.2012-1287","article-title":"Structural insights into aldosterone synthase substrate specificity and targeted inhibition","volume":"27","author":"Strushkevich","year":"2013","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.apsb.2021.09.013_bib48","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0162-0134(01)00331-2","article-title":"Modelling of three-dimensional structures of cytochromes P450 11B1 and 11B2","volume":"87","author":"Belkina","year":"2001","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.apsb.2021.09.013_bib49","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1124\/dmd.107.016501","article-title":"CYP3A4-mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ\u2012CYP3A4 adduct and alteration of the enzyme kinetic profile","volume":"36","author":"Kang","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2021.09.013_bib50","doi-asserted-by":"crossref","first-page":"1700332","DOI":"10.1002\/mnfr.201700332","article-title":"Ursolic acid, a natural nutraceutical agent, targets caspase3 and alleviates inflammation-associated downstream signal transduction","volume":"61","author":"Ma","year":"2017","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.apsb.2021.09.013_bib51","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1021\/acs.jmedchem.8b00328","article-title":"Discovery of novel pyrazole-based selective aldosterone synthase (CYP11B2) inhibitors: a new template to coordinate the heme-iron motif of CYP11B2","volume":"61","author":"Sakakibara","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.09.013_bib52","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1021\/acsmedchemlett.9b00152","article-title":"Development of highly selective pyrimidine-based aldosterone synthase (CYP11B2) inhibitors","volume":"10","author":"Sparks","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2021.09.013_bib53","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2174\/1568026611313120003","article-title":"Progress towards clinically useful aldosterone synthase inhibitors","volume":"13","author":"Cerny","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.apsb.2021.09.013_bib54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ahj.2020.03.016","article-title":"Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease","volume":"224","author":"Boden","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.apsb.2021.09.013_bib55","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/HYPERTENSIONAHA.116.07660","article-title":"Estrogen signaling in the adrenal cortex: implications for blood pressure sex differences","volume":"68","author":"Caroccia","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.apsb.2021.09.013_bib56","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.3390\/molecules16043146","article-title":"Screening for compounds with aromatase inhibiting activities from Atractylodes macrocephala Koidz","volume":"16","author":"Jiang","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2021.09.013_bib57","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/0003-4819-87-4-398","article-title":"Pathophysiology of spironolactone-induced gynecomastia","volume":"87","author":"Rose","year":"1977","journal-title":"Ann Intern Med"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521003555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521003555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:51:31Z","timestamp":1761929491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383521003555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2211383521003555"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2021.09.013","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atractylenolide-I covalently binds to CYP11B2, selectively inhibits aldosterone synthesis, and improves hyperaldosteronism","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2021.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}